Prince William rallies against climate denialism at Earthshot Prize

Prince William rallies against climate denialism at Earthshot Prize

The winners of the environmental awards,established by the heir to the British throne,each received $1.91 million in prize money after being announced in Singapore.

  • byChris Barrett

Latest

Shedding fat without losing muscle is next weight-loss target for pharma giant

Shedding fat without losing muscle is next weight-loss target for pharma giant

Muscle-mass preservation is becoming a hot new area in obesity medicine.

  • byMadison Muller andCynthia Koons
It’s throwing its weight around,but can Ozempic reshape our economy?

It’s throwing its weight around,but can Ozempic reshape our economy?

From health to fast food,investors are starting to question which companies will be slimmed thanks to weight-loss drugs.

  • byEmma Koehn andColin Kruger
Our biggest healthcare company says it isn’t scared of Ozempic

Our biggest healthcare company says it isn’t scared of Ozempic

CSL has outlined its growth strategy to investors and played down concerns about weight-loss drugs’ impact on some of its key products.

  • byEmma Koehn
‘Every reason to be grumpy’:CSL defends share price to investors

‘Every reason to be grumpy’:CSL defends share price to investors

Shareholders have grilled the biotech giant about its long-term strategy as the stock sits close to 10 per cent lower for the year.

  • byEmma Koehn
CSL aims to get better bang for buck from plasma

CSL aims to get better bang for buck from plasma

The ASX heavyweight and the nation’s largest healthcare company is looking to make its operations more efficient to counter inflation and currency woes.

  • byEmma Koehn
Advertisement
The country’s largest healthcare company has big questions to answer

The country’s largest healthcare company has big questions to answer

Blood plasma giant CSL will set the tone for earnings season this week,having been hit hard after a profit downgrade earlier this year.

  • byEmma Koehn
Mesoblast shares tank after US FDA delays stem cell approval again

Mesoblast shares tank after US FDA delays stem cell approval again

The US regulator has again asked for more data on the stem cell treatment maker’s flagship product,which was blocked from approval in 2020 for the same reason.

  • byEmma Koehn andJessica Yun
How an old Disney movie inspired Daniya to create a medical robot

How an old Disney movie inspired Daniya to create a medical robot

Whether it’s a medical robot or a high-tech weather station,HSC technology subjects are an opportunity to indulge your passion.

CBD oil and skincare maker has its eye on Australia

CBD oil and skincare maker has its eye on Australia

Dragonfly Biosciences wants to bring more of its cannabis-based products to local pharmacies.

  • byEmma Koehn
CSL profits dragged down by currency woes

CSL profits dragged down by currency woes

The biotechnology giant has downgraded its profit guidance after taking a blow from unfavourable currency movements as it competes for plasma donations.

  • byMillie Muroi